Literature DB >> 3202902

A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells.

R J Knox1, F Friedlos, M Jarman, J J Roberts.   

Abstract

Walker tumour cells in vivo or in vitro are exceptionally sensitive to the monofunctional alkylating agent 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) (Cobb LM et al., Biochem Pharmacol 18: 1519-1527, 1969). CB 1954 forms DNA interstrand crosslinks in a time-dependent manner in Walker tumour cells but not in non-toxically affected Chinese hamster V79 cells [(Roberts JJ et al., Biochem Biophys Res Commun 140: 1073-1078, 1986)]. However, co-culturing Chinese hamster V79 cells with Walker cells in the presence of CB 1954 renders the hamster cells sensitive to CB 1954 and leads to the formation of interstrand crosslinks in their DNA, findings indicative of the formation by Walker cells of a diffusible toxic metabolite of CB 1954. A flavoprotein, of molecular weight 33.5 kDa as estimated by SDS-polyacrylamide gel electrophoresis, has been isolated from Walker cells and identified as a form of NAD(P)H dehydrogenase (quinone) (DT diaphorase, EC 1.6.99.2). This enzyme, in the presence of NADH or NADPH, catalyses the aerobic reduction of CB 1954 to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide. This new compound can form interstrand crosslinks in the DNA of Chinese hamster V79 cells to which it is also highly toxic.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3202902     DOI: 10.1016/0006-2952(88)90335-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  24 in total

Review 1.  Molecular mechanisms of drug resistance.

Authors:  J D Hayes; C R Wolf
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

Review 2.  Cellular senescence and cancer chemotherapy resistance.

Authors:  Ryan R Gordon; Peter S Nelson
Journal:  Drug Resist Updat       Date:  2012-02-23       Impact factor: 18.500

3.  Functional Annotation of a Presumed Nitronate Monoxygenase Reveals a New Class of NADH:Quinone Reductases.

Authors:  Jacob Ball; Francesca Salvi; Giovanni Gadda
Journal:  J Biol Chem       Date:  2016-08-08       Impact factor: 5.157

Review 4.  Potent and tumor specific: arming bacteria with therapeutic proteins.

Authors:  Nele Van Dessel; Charles A Swofford; Neil S Forbes
Journal:  Ther Deliv       Date:  2015-03

Review 5.  Antibody-directed enzyme prodrug therapy.

Authors:  K D Bagshawe
Journal:  Clin Pharmacokinet       Date:  1994-11       Impact factor: 6.447

6.  The nitroreductase system of inducible targeted ablation facilitates cell-specific regenerative studies in zebrafish.

Authors:  David T White; Jeff S Mumm
Journal:  Methods       Date:  2013-03-27       Impact factor: 3.608

7.  Prodrugs in Cancer Chemotherapy.

Authors:  Richard J Knox; Tom A Connors
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

Review 8.  The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT).

Authors:  R J Knox; F Friedlos; M P Boland
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

Review 9.  Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs).

Authors:  W A Denny; W R Wilson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

10.  CNOB/ChrR6, a new prodrug enzyme cancer chemotherapy.

Authors:  Steve H Thorne; Yoram Barak; Wenchuan Liang; Michael H Bachmann; Jianghong Rao; Christopher H Contag; A Matin
Journal:  Mol Cancer Ther       Date:  2009-02-03       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.